Cover Image
Read Now

Patient group input submissions: Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited)

Bibliographic Details
Corporate Authors: Multiple Sclerosis Society of Canada, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, 2017
Series:CADTH common drug review
Subjects:
Patient Participation
Canada
Multiple Sclerosis, Chronic Progressive / Drug Therapy
Treatment Outcome
Antibodies, Monoclonal, Humanized / Therapeutic Use
Patient Satisfaction
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01434nam a2200325 u 4500
001 EB001872056
003 EBX01000000000000001035427
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190824 r ||| eng
245 0 0 |a Patient group input submissions: Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited)  |h Elektronische Ressource 
246 3 1 |a Patient group input submissions for Ocrevus 
246 3 1 |a Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited) 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2017, 2017 
300 |a 1 PDF file (5 pages) 
653 |a Patient Participation 
653 |a Canada 
653 |a Multiple Sclerosis, Chronic Progressive / drug therapy 
653 |a Treatment Outcome 
653 |a Antibodies, Monoclonal, Humanized / therapeutic use 
653 |a Patient Satisfaction 
710 2 |a Multiple Sclerosis Society of Canada 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
500 |a "Indication: Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features." 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK534396  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 140 
082 0 |a 700 

Similar Items